Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

NCT ID: NCT04930094

Last Updated: 2025-10-31

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 355 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-06
• Study Completion Date: 2027-07-05

Brief Summary

This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)

Detailed Description

Randomized, parallel-group, double-blind, placebo-controlled, multi-center, Phase III study to evaluate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)

Conditions

Giant Cell Arteritis (GCA)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Secukinumab 300 mg

Secukinumab 300 mg s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a specified 26-week prednisone taper regimen. After the 26-week prednisone taper, participants will continue to receive placebo to prednisone until Week 52.

Group Type: EXPERIMENTAL

Secukinumab 300 mg

Intervention Type: BIOLOGICAL

Secukinumab 300 mg

Placebo

Placebo to secukinumab s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Placebo will be given in combination with a specified 52-week prednisone taper regimen.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo

Secukinumab 150 mg

Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a specified 26-week prednisone taper regimen. After the 26-week prednisone taper, participants will continue to receive placebo to prednisone until Week 52.

Group Type: EXPERIMENTAL

Secukinumab 150 mg

Intervention Type: BIOLOGICAL

Secukinumab

Interventions

Secukinumab 300 mg

Secukinumab 300 mg

Intervention Type: BIOLOGICAL

Placebo

Placebo

Intervention Type: OTHER

Secukinumab 150 mg

Secukinumab

Intervention Type: BIOLOGICAL

Other Intervention Names

AIN457; Placebo Comparator; AIN457

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent must be obtained prior to participation in the study.

2. Patient must be able to understand and communicate with the investigator and comply with the requirements of the study.

3. Male or non-pregnant, non-lactating female patients at least 50 years of age.

4. Diagnosis of GCA based on meeting all of the following criteria:

• Age at onset of disease ≥ 50 years.
• Unequivocal cranial symptoms of GCA (e.g., new-onset localized headache, scalp or temporal artery tenderness, permanent or temporary ischemia-related vision loss, or otherwise unexplained mouth or jaw pain upon mastication), and/or unequivocal symptoms of polymyalgia rheumatica (PMR) (defined as shoulder and/or hip girdle pain associated with inflammatory morning stiffness) and/or symptoms of limb ischemia (claudication).
• TAB revealing features of GCA and/or cross-sectional imaging study such as ultrasound (e.g., cranial or axillary), MRI/MRA, CTA, or PET-CT with evidence of vasculitis.

5. Active disease as defined by meeting both of the following within 6 weeks of BSL (see Section 8.1 for details)

• Presence of signs or symptoms attributed to active GCA and not related to prior damage (e.g., visual loss that occurred prior to 6 weeks before BSL without new findings occurring within 6 weeks of BSL)
• Elevated ESR ≥ 30 mm/hr or CRP ≥ 10 mg/L attributed to active GCA or active GCA on TAB or on imaging study.

6. Patients to meet definition of new-onset GCA or relapsing GCA:

• Definition of new-onset GCA*: GCA that is diagnosed within 6 weeks of BSL visit
• Definition relapsing GCA: GCA diagnosed > 6 weeks before BSL visit and following institution of an appropriate treatment course for GCA, participant has experienced recurrence of active symptoms or signs of disease after resolution.

• The 6-week timeframe is to be calculated from the date of suspected GCA diagnosis. Suspected diagnosis is defined as date when GC therapy was initiated.

7. Patients' current GCA episode should be treatable with a dose of prednisone (or equivalent) designed to adequately achieve disease control in accordance with international guidelines. If this is not possible due to concerns regarding GC toxicity, the patient should not be enrolled. It must be medically appropriate for the patient to receive prednisone (or equivalent) 20 mg-60 mg daily (or equivalent) at BSL.

8. Patients taking MTX (≤ 25 mg/week) are allowed to continue their medication provided they have taken it for at least 2 months and are on a stable dose for at least 4 weeks prior to randomization and if they are on stable folic acid treatment before randomization.

Exclusion Criteria

1. Pregnant or nursing (lactating) women where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.

2. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during study treatment or longer if required by locally approved prescribing information (e.g., in European Union (EU) 20 weeks after treatment discontinuation). Also, contraception should be used in accordance with locally approved prescribing information of concomitant medications administered (e.g., Rescue Treatment). Effective contraception methods include:

• Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
• Bilateral oophorectomy with or without hysterectomy, total hysterectomy or bilateral salpingectomy at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment are they not considered to be of child-bearing potential.
• Bilateral tubal occlusion, Bilateral tubal ligation (at least six weeks before taking study treatment.
• Male sterilization (vasectomy) of male partner(s) of the female participant at least 6 months prior to screening.
• Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps). NOTE: for United Kingdom: with spermicidal foam/gel/film/cream/vaginal suppository.
• Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example, hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS). In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
• Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms). Women participants are considered not of child-bearing potential if they are post-menopausal or have had, surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks prior to first dose of study treatment in the study . In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered to be not of child-bearing potential.

If local regulations are more stringent than the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the Informed Consent Form (ICF).

3. Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor.

4. Patients treated with any cell-depleting therapies.

5. Previous participation in a clinical trial where the outcome of treatment with the GCA drug is unknown. This does not include trials where the treatment for GCA was GCs, MTX, leflunomide or azathioprine

6. Patients who have been treated with inhibitors directly targeting IL-1, or IL-1 receptor, IL-12 and IL-23, or abatacept within 4 weeks or within 5 half-lives of the drug (whichever is longer) prior to BSL.

7. Treatment with tocilizumab, other IL-6/IL6-R inhibitor or JAK inhibitor within 12 weeks or within 5 half-lives of the drug (whichever is longer) prior to BSL, or if the patient did not respond to or experienced a relapse during treatment any time before BSL.

8. Any treatment received for GCA in which patient did not respond to treatment or experienced a relapse while on that treatment any time before BSL. This also includes patients who were treated in a clinical trial for GCA. Patients who failed on treatment with GCs, MTX, leflunomide and/or azathioprine may be included.

9. Patients treated with i.v. immunoglobulins or plasmapheresis within 8 weeks prior to BSL.

10. Patients treated (i.e. systemic therapy) with cyclophosphamide or hydroxychloroquine within 6 months prior to BSL, or tacrolimus, everolimus, cyclosporine A, azathioprine, sulfasalazine, mycophenolate mofetil within 4 weeks prior to BSL.

11. Patients treated with leflunomide within 8 weeks of BSL unless a cholestyramine washout has been performed in which case the patient must be treated within 4 weeks of BSL.

13. Patients requiring or anticipated to require systemic chronic glucocorticoid therapy or pulses of glucocorticoids for reasons other than GCA (e.g., COPD, asthma, planned surgery) at screening or randomization.

14. Criterion removed in protocol V01.

15. Patients requiring chronic (i.e., not occasional "prn") high potency opioid analgesics for pain management.

16. Use of other investigational drugs within 5 half-lives of enrollment or within 30 days (e.g. small molecules) or until the expected pharmacodynamic effect has returned to BSL (e.g., biologics), whichever is longer; or longer if required by local regulations.

17. History of hypersensitivity or contraindication to any of the study treatments or its excipients or to drugs of similar chemical classes.

18. Active IBD or other ongoing inflammatory diseases other than GCA that might confound the evaluation of the benefit of secukinumab therapy, including uveitis at screening or randomization.

19. Major ischemic event (e.g., myocardial infarction, stroke, etc.) or transient ischemic attack (TIA) (except ischemia-related vision loss), related or unrelated to GCA, within 12 weeks of screening.

20. Confirmed diagnosis of any primary form of systemic vasculitis, other than GCA.

21. Any other systemic biologics (e.g., denosumab, TNFα inhibitors) within 4 weeks or within 5 half-lives of the drug (whichever is longer) prior to BSL, or anticipated use of a systemic biologic prior to EOS

22. Active ongoing diseases which in the opinion of the investigator immunocompromises the patient and/or places the patient at unacceptable risk for treatment with immunomodulatory therapy.

23. Significant medical problems or diseases, including but not limited to the following: uncontrolled hypertension (≥ 160/95 mmHg), congestive heart failure (New York Heart Association (NYHA) status of class III or IV) and uncontrolled diabetes mellitus.

24. History of clinically significant liver disease or liver injury as indicated by abnormal liver function tests (LFTs) such as Aspartate Aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) or serum bilirubin. The investigator should be guided by the following criteria:

• SGOT (AST) and SGPT (ALT) may not exceed 3 × the upper limit of normal (ULN). A single parameter elevated up to and including 3 × ULN should be re-checked once more as soon as possible, and in all cases, at least prior to randomization, to rule-out laboratory error.
• Alkaline phosphatase may not exceed 2 × ULN. An elevation up to and including 2 × ULN should be re-checked once more as soon as possible, and in all cases, at least prior to randomization, to rule-out laboratory error.
• Total bilirubin may not exceed 2 × ULN. If the total bilirubin concentration is increased above 2 × ULN, total bilirubin should be differentiated into the direct and indirect reacting bilirubin.

25. Criterion removed in protocol V01

26. Screening total WBC count < 3,000/μL, or platelets < 100,000/μL or neutrophils < 1,500/μL or Hgb < 8.3 g/dL (83 g/L).

27. Active infections during the last 2 weeks prior to randomization.

28. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold Plus test. Patients with a positive test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active TB. If the test result is indeterminate, the investigator may repeat the test once or may proceed directly to perform the work-up for TB as per local procedures. If presence of latent TB is established then treatment according to local country guidelines must be initiated prior to randomization.

29. Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C (if not treated and cured) at screening or randomization

30. History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).

31. Live vaccinations (e.g., monkey pox vaccine, oral polio vaccine, varicella/zoster vaccines) within 6 weeks prior to BSL, or planned or anticipated potential need for live vaccination during study participation until 12 weeks after last study treatment administration.

32. Current severe progressive or uncontrolled disease, which in the judgment of the clinical investigator renders the patient unsuitable for the trial.

33. Any medical or psychiatric condition, which, in the investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol.

34. Donation or loss of 400 mL or more of blood within 8 weeks before randomization.

35. History or evidence of ongoing alcohol or drug abuse, within the last 6 months before randomization.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Cedars Sinai Medical Center

Los Angeles, California, United States

IRIS Research and Development

Plantation, Florida, United States

Sarasota Arthritis Res Ctr

Sarasota, Florida, United States

Novartis Investigative Site

Iowa City, Iowa, United States

University Of Iowa

Iowa City, Iowa, United States

Osteoporosis and Clinical Trial Ctr

Hagerstown, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

West Tennessee Research Institute

Jackson, Tennessee, United States

Precision Comp Clin Research

Grapevine, Texas, United States

Advanced Rheumatology of Houston

Spring, Texas, United States

Novartis Investigative Site

La Plata, Buenos Aires, Argentina

Novartis Investigative Site

Capital Federal, , Argentina

Novartis Investigative Site

Southport, Queensland, Australia

Novartis Investigative Site

Hobart, Tasmania, Australia

Novartis Investigative Site

Heidelberg Heights, Victoria, Australia

Novartis Investigative Site

Malvern East, Victoria, Australia

Novartis Investigative Site

Murdoch, Western Australia, Australia

Novartis Investigative Site

Liverpool, , Australia

Novartis Investigative Site

Parramatta, , Australia

Novartis Investigative Site

Innsbruck, Tyrol, Austria

Novartis Investigative Site

Graz, , Austria

Novartis Investigative Site

Leuven, , Belgium

Novartis Investigative Site

Liège, , Belgium

Novartis Investigative Site

Juiz de Fora, Minas Gerais, Brazil

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil

Novartis Investigative Site

Sao Jose Rio Preto, São Paulo, Brazil

Novartis Investigative Site

Plovdiv, , Bulgaria

Novartis Investigative Site

Plovdiv, , Bulgaria

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Sherbrooke, Quebec, Canada

Novartis Investigative Site

Trois-Rivières, Quebec, Canada

Novartis Investigative Site

Brno, , Czechia

Novartis Investigative Site

Prague, , Czechia

Novartis Investigative Site

Prague, , Czechia

Novartis Investigative Site

Uherské Hradiště, , Czechia

Novartis Investigative Site

Aarhus N, , Denmark

Novartis Investigative Site

Esbjerg, , Denmark

Novartis Investigative Site

Vejle, , Denmark

Novartis Investigative Site

Tallinn, , Estonia

Novartis Investigative Site

Tartu, , Estonia

Novartis Investigative Site

Helsinki, , Finland

Novartis Investigative Site

Kuopio, , Finland

Novartis Investigative Site

Lahti, , Finland

Novartis Investigative Site

Turku, , Finland

Novartis Investigative Site

Brest, , France

Novartis Investigative Site

Dijon, , France

Novartis Investigative Site

Le Mans, , France

Novartis Investigative Site

Lille, , France

Novartis Investigative Site

Marseille, , France

Novartis Investigative Site

Nantes, , France

Novartis Investigative Site

Paris, , France

Novartis Investigative Site

Paris, , France

Novartis Investigative Site

Strasbourg, , France

Novartis Investigative Site

Toulouse, , France

Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Novartis Investigative Site

Würzburg, Bavaria, Germany

Novartis Investigative Site

Dresden, Saxony, Germany

Novartis Investigative Site

Berlin, , Germany

Novartis Investigative Site

Bonn, , Germany

Novartis Investigative Site

Dresden, , Germany

Novartis Investigative Site

Erlangen, , Germany

Novartis Investigative Site

Herne, , Germany

Novartis Investigative Site

Ludwigshafen, , Germany

Novartis Investigative Site

Athens, , Greece

Novartis Investigative Site

Guatemala City, , Guatemala

Novartis Investigative Site

Budapest, , Hungary

Novartis Investigative Site

Debrecen, , Hungary

Novartis Investigative Site

Pécs, , Hungary

Novartis Investigative Site

Szeged, , Hungary

Novartis Investigative Site

Tel Aviv, , Israel

Novartis Investigative Site

Brescia, BS, Italy

Novartis Investigative Site

Cona, FE, Italy

Novartis Investigative Site

Florence, FI, Italy

Novartis Investigative Site

Milan, MI, Italy

Novartis Investigative Site

Siena, SI, Italy

Novartis Investigative Site

Gjettum, , Norway

Novartis Investigative Site

Moss, , Norway

Novartis Investigative Site

Bydgoszcz, , Poland

Novartis Investigative Site

Krakow, , Poland

Novartis Investigative Site

Lisbon, , Portugal

Novartis Investigative Site

Ponte de Lima, , Portugal

Novartis Investigative Site

Santiago Compostela, A Coruna, Spain

Novartis Investigative Site

Sabadell, Barcelona, Spain

Novartis Investigative Site

Bilbao, Bizkaia, Spain

Novartis Investigative Site

Santander, Cantabria, Spain

Novartis Investigative Site

Badalona, Catalonia, Spain

Novartis Investigative Site

Pamplona, Navarre, Spain

Novartis Investigative Site

Barcelona, , Spain

Novartis Investigative Site

Barcelona, , Spain

Novartis Investigative Site

Madrid, , Spain

Novartis Investigative Site

Madrid, , Spain

Novartis Investigative Site

Valencia, , Spain

Novartis Investigative Site

Malmo, , Sweden

Novartis Investigative Site

Basel, , Switzerland

Novartis Investigative Site

Geneva, , Switzerland

Novartis Investigative Site

Sankt Gallen, , Switzerland

Novartis Investigative Site

Zurich, , Switzerland

Novartis Investigative Site

Istanbul, Fatih, Turkey (Türkiye)

Novartis Investigative Site

Istanbul, Pendik, Turkey (Türkiye)

Novartis Investigative Site

Ankara, Sihhiye-Altindag, Turkey (Türkiye)

Novartis Investigative Site

Edinburgh, Scotland, United Kingdom

Novartis Investigative Site

Stoke-on-Trent, Staffordshire, United Kingdom

Novartis Investigative Site

Newcastle upon Tyne, Tyne and Wear, United Kingdom

Novartis Investigative Site

Dundee, , United Kingdom

Countries

United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Czechia; Denmark; Estonia; Finland; France; Germany; Greece; Guatemala; Hungary; Israel; Italy; Norway; Poland; Portugal; Spain; Sweden; Switzerland; Turkey (Türkiye); United Kingdom

Other Identifiers

2024-510744-31-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

CAIN457R12301

Identifier Type: -

Identifier Source: org_study_id